GMAB:NASDAQGenmab A/S Analysis
Data as of 2026-05-19 - not real-time
$25.83
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
Genmab A/S (GMAB) trades at $25.83, well below its discounted cash‑flow fair value of $41.73, indicating a material undervaluation gap that supports a buy case. Technical signals are bearish in the short run – the 20‑day SMA (26.77) sits above price, RSI‑14 is 40.6 (below the 50 neutral line), and MACD shows a bearish histogram – yet the stock rests just above its computed support of $25.34, limiting downside risk.
Fundamentally the company posted a 25% YoY revenue jump to $896 M in Q1 2026, maintains a 93.3% gross margin and a 21% profit margin, and its DCF fair value suggests a potential upside of roughly $15.9 B in market cap. Strategic catalysts include a strong oncology pipeline, multiple collaborations with major pharma players, and a recent analyst upgrade to “Buy” with a $30.50 price target, reinforcing a longer‑term bullish thesis.
Fundamentally the company posted a 25% YoY revenue jump to $896 M in Q1 2026, maintains a 93.3% gross margin and a 21% profit margin, and its DCF fair value suggests a potential upside of roughly $15.9 B in market cap. Strategic catalysts include a strong oncology pipeline, multiple collaborations with major pharma players, and a recent analyst upgrade to “Buy” with a $30.50 price target, reinforcing a longer‑term bullish thesis.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 5/10
Key Factors
- bearish MACD histogram and RSI below 50 suggest limited upside in the next weeks
- price is near the computed support level, reducing immediate downside exposure
- volume trend is increasing, providing reasonable liquidity for a short‑term position
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- DCF fair value of $41.73 versus current price creates a ~57% discount
- robust 25% YoY revenue growth and expanding oncology pipeline
- analyst upgrades and a $30.50 price target signal market confidence
Long Term
> 3 yearsPositive
Model confidence: 8/10
Key Factors
- sustained high gross margin (93%) and profit margin (21%) support durable earnings power
- strategic collaborations with AbbVie, Pfizer, BMS, Amgen and others broaden market reach
- low dividend payout aligns with a reinvest‑in‑growth strategy typical for high‑growth biotech
Key Metrics & Analysis
Financial Health
Revenue Growth25.30%
Profit Margin21.05%
P/E Ratio19.6
ROE14.96%
ROA8.48%
Debt/Equity94.17
P/B Ratio2.8
Op. Cash Flow$902.0M
Free Cash Flow$830.4M
Industry P/E27.2
Technical Analysis
TrendBearish
RSI40.6
Support$25.34
Resistance$28.28
MA 20$26.77
MA 50$26.97
MA 200$29.05
MACDBearish
VolumeIncreasing
Fear & Greed Index89.38
Valuation
Fair Value$41.73
Target Price$37.55
Upside/Downside45.36%
GradeUndervalued
TypeGrowth
Risk Assessment
Beta0.93
Volatility31.57%
Sector RiskHigh
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.